At the news
? NEUTRALIMPACT 2/10 DEFA14A filed Apr 7, 2026 at 07:01 ET
Passage Bio, Inc. filed a definitive proxy statement for its 2026 Annual Meeting, which includes the election of two Class III directors, ratification of its independent auditor, and approval of executive compensation. This is a routine corporate governance filing.
- Election of two Class III directors: Athena Countouriotis, M.D. and Sandip Kapadia
- Ratification of KPMG LLP as independent registered public accounting firm for fiscal year 2026
- Approval of executive officer compensation on a non-binding advisory basis
- Approval of frequency for future advisory votes on executive compensation
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access